GoKawiilScience Corporation implants PRIMA chip in first Stargardt disease patient
Science Corporation CEO Max Hodak announced the company implanted its PRIMA vision-restoring chip into its first patient with Stargardt disease, an inherited condition that gradually destroys central vision. The implant was performed in May at Sydney Eye Hospital in Australia as part of an ongoing clinical trial, extending use of a device already sold in Europe for geographic atrophy.
GoKawiil's interpretation of the reporting above, not reported fact.
Hodak, Neuralink's former president, frames PRIMA as part of a broader brain-computer interface strategy that treats retinal prostheses, cochlear implants and motor prostheses as variations on the same underlying technology. If successful, this could position the company to expand into additional currently incurable retinal diseases beyond its approved use, though the Stargardt application remains experimental and unproven in a formal trial setting.
- Science Corporation implanted its PRIMA chip in its first Stargardt disease patient in May at Sydney Eye Hospital.
- PRIMA is already commercially available in Europe for geographic atrophy, a form of age-related macular degeneration.
- CEO Max Hodak describes PRIMA as part of a broader brain-computer interface strategy spanning multiple sensory and motor prosthetics.
Source: techcrunch.com — Aisha Malik, 2026-10-13
Published there as: “Science Corporation implants its vision-restoring chip in its first Stargardt disease patient”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.